PLEASANTON, Calif., Oct. 27 /PRNewswire-FirstCall/ -- Thoratec Corporation , a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, today announced that it will report its operating results for the third quarter and first nine months of fiscal 2009 on Wednesday, November 4.
The teleconference can be accessed by calling (719) 325-4833, passcode 4647776. Please dial in 10-15 minutes prior to the beginning of the call. The webcast will be available on the Internet at http://phx.corporate-ir.net/phoenix.zhtml?p=iroleventDetails&c=95989&eventID=2492660, or at http://www.thoratec.com.
Thoratec Corporation is a world leader in therapies to address advanced-stage heart failure. The company’s product lines include the Thoratec(R) VAD (Ventricular Assist Device) and HeartMate(R) LVAS (Left Ventricular Assist System), with more than 14,000 devices implanted in patients suffering from heart failure. Additionally, its International Technidyne Corporation (ITC) division is a leader in point-of-care blood testing and skin incision products. Thoratec is headquartered in Pleasanton, California. For more information, visit the company’s web sites at http://www.thoratec.com or http://www.itcmed.com.
CONTACT: David Smith, Executive Vice President, Chief Financial Officer of
Thoratec Corporation, +1-925-847-8600; or Neal B. Rosen of Ruder-Finn,
+1-415-692-3058, for Thoratec Corporation
Web site: http://www.thoratec.com/
